Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 2/20 | 0.59 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.59 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.59 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.59 |
| ▸ | PTGS2 | P35354 | 9/20 | 0.58 |
| ▸ | PTGS1 | P23219 | 8/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.50 |
| ▸ | CA12 | O43570 | 3/20 | 0.48 |
| ▸ | CA2 | P00918 | 3/20 | 0.48 |
| ▸ | CA9 | Q16790 | 3/20 | 0.48 |
| ▸ | CA1 | P00915 | 2/20 | 0.48 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2397216 | 0.78 | JAK2 (0.42) | PIK3CDPIK3CAPIK3CBPIK3CGMEN1 | |
| SCHEMBL2395876 | 0.75 | RAB9A (0.49) | MEN1KMT2A | |
| SCHEMBL2393782 | 0.75 | MEN1 (0.60) | PIK3CDPIK3CAPIK3CBPIK3CGPTGS2 | |
| SCHEMBL48391 | 0.75 | PIK3CG (1.00) | PIK3CDPIK3CAPIK3CBPIK3CGMEN1 | |
| SCHEMBL6800972 | 0.74 | ALDH1A1 (0.54) | MEN1KMT2A | |
| SCHEMBL2395898 | 0.74 | MEN1 (0.58) | PIK3CDPIK3CAPIK3CBPIK3CGPTGS2 | |
| SCHEMBL2395156 | 0.74 | CDK2 (0.59) | PIK3CDPIK3CAPIK3CBPIK3CGPTGS2 | |
| SCHEMBL6263668 | 0.74 | PTGS2 (1.00) | PTGS2PTGS1CHRNA7CA12CA2 | |
| SCHEMBL7843199 | 0.74 | PTGS2 (1.00) | PTGS2PTGS1CHRNA7CA12CA2 | |
| SCHEMBL2397832 | 0.73 | MEN1 (0.61) | PIK3CDPIK3CAPIK3CBPIK3CGPTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8017608-B2 | 5-Phenylthiazole derivatives and their use as p13 kinase inhibitors | NOVARTIS AG (CH) | 2011-09-13 | — | — | US | disclosed |
| CN-100569770-C | 5-phenyl thiazole derivant and they purposes as the PI3 kinase inhibitor | NOVARTIS AG (CH) | 2009-12-16 | — | — | CN | disclosed |
| EP-1608647-B1 | 5-PHENYLTHIAZOLE DERIVATIVES AND THEIR USE AS P13 KINASE INHIBITORS | NOVARTIS AG (CH) | 2008-01-09 | — | — | EP | disclosed |
| US-20060148822-A1 | 5-Phenylthiazole derivatives and their use as p13 kinase inhibitors | NOVARTIS AG (CH) | 2006-07-06 | — | — | US | disclosed |
| CN-1780832-A | 5-phenylthiazole derivatives and their use as PI3 kinase inhibitors | NOVARTIS AG (CH) | 2006-05-31 | — | — | CN | disclosed |
| EP-1608647-A1 | 5-PHENYLTHIAZOLE DERIVATIVES AND THEIR USE AS P13 KINASE INHIBITORS | Novartis AG (CH) | 2005-12-28 | — | — | EP | disclosed |
| WO-2004078754-A1 | 5-PHENYLTHIAZOLE DERIVATIVES AND THEIR USE AS P13 KINASE INHIBITORS | NOVARTIS AG (CH) | 2004-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060148822-A1 | 5-Phenylthiazole derivatives and their use as p13 kinase inhibitors | MAP3K13, AKT3, MAP3K3 | PIK3CD 42/4885PIK3CA 4/4885PIK3CB 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.